IanBWaltersMD

PubMed

• 150 citations
  Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
  Riccardo Lencioni, Robert Montal, Ferran Torres, Joong-Won Park, Thomas Decaens, Jean-Luc Raoul, Masatoshi Kudo, Charissa Chang, José Ríos, Valérie Boige, Eric Assenat...> ;Journal of Hepatology. 2017 Jun 1
• 241 citations
  Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
  Masatoshi Kudo, Guohong Han, Richard S. Finn, Ronnie T.P. Poon, Jean-Frédéric Blanc, Lunan Yan, Jijin Yang, Ligong Lu, Won Young Tak, Xiaoping Yu, Joon-Hyeok Lee, Shi-...> ;Hepatology. 2014 Nov 1
• 20 citations
  Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma
  Jean-Luc Raoul, Joong-Won Park, Yoon-Koo Kang, Richard S. Finn, Jun Suk Kim, Winnie Yeo, Blase N. Polite, Yee Chao, Ian Walters, Christine Baudelet, Riccardo Lencioni> ;Liver Cancer. 2014 Apr 16
• 462 citations
  Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-...
  Josep M. Llovet, Thomas Decaens, Jean-Luc Raoul, Eveline Boucher, Masatoshi Kudo, Charissa Chang, Yoon-Koo Kang, Eric Assenat, H. Y. Lim, Valérie Boige, Philippe Mathu...> ;Journal of Clinical Oncology. 2013 Oct 1
• 590 citations
  Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
  Philip J. Johnson, Shukui Qin, Joong-Won Park, Ronnie T.P. Poon, Jean-Luc Raoul, Philip A. Philip, Chih-Hung Hsu, Tsung Hui Hu, Jeong Heo, Jianming Xu, Ligong Lu, Yee ...> ;Journal of Clinical Oncology. 2013 Oct 1
• Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
  Finn RS, Kang Y, Mulcahy M, Polite BN, Lim HY, Walters I, Baudelet C, Manekas D, Park J> ;Clin. Cancer Res.. 2012-04-01
• 103 citations
  Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF...
  Elizabeth Allen, Ian Walters, Douglas Hanahan> ;Clinical Cancer Research. 2011 Aug 15
• 45 citations
  Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
  Raman Sood, Harry Carloss, Robert Kerr, Jose V. Lopez, Martin W. Lee, Mark Druck, Ian B. Walters, Stephen J. Noga> ;American Journal of Hematology. 2009 Oct 1
• An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC).
  Raoul JL, Finn RS, Kang YK, Park JW, Harris R, Coric V, Donica M, Walters I> ;J. Clin. Oncol.. 2009-05-20
• 50 citations
  Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
  Jeffrey L. Wolf, Paul G. Richardson, Michael W. Schuster, Annette LeBlanc, Ian Walters, David S Battleman> ;Clinical Advances in Hematology & Oncology. 2008 Oct 1
• 39 citations
  An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma.
  Therese M. Conner, QuynhChau D. Doan, Ian Walters, Annette L. LeBlanc, Roy A. Beveridge> ;Clinical Lymphoma & Myeloma. 2008 Jun 1
• Utility of bortezomib retreatment among patients with refractory multiple myeloma.
  Wolf JL, Leblanc Mt AL, Battleman DS, Davis B, Lyandres JR, Walters IB> ;J. Clin. Oncol.. 2006-06-20
• A phase IV, open-label trial using bortezomib for retreatment of patients (pts) with multiple myeloma (MM) following an initial response to bortezomib.
  Druck M, Walters IB, Carloss H, Sood R, Leblanc AL, Noga SJ> ;J. Clin. Oncol.. 2006-06-20
• 57 citations
  Narrowband (312-nm) UV-B Suppresses Interferon γ and Interleukin (IL) 12 and Increases IL-4 Transcripts: Differential Regulation of Cytokines at the Single-Cell Level
  Ian B. Walters, Maki Ozawa, Irma Cardinale, Patricia Gilleaudeau, William L. Trepicchio, Judith L. Bliss, James G. Krueger> ;Archives of Dermatology. 2003 Feb 1
• 131 citations
  Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling
  Judith L. Oestreicher, Ian B. Walters, Toyoko Kikuchi, Patricia Gilleaudeau, J Surette, Ullrich S. Schwertschlag, Andrew J. Dorner, James G. Krueger, William L. Trepic...> ;The Pharmacogenomics Journal. 2001 Jan 1
• 94 citations
  Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis.
  James G. Krueger, Ian B. Walters, Megumi Miyazawa, Patricia Gilleaudeau, John Hakimi, Susan Light, Amelia Sherr, Alice B. Gottlieb> ;Journal of the American Academy of Dermatology. 2000 Sep 1
• 167 citations
  Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions
  William L. Trepicchio, Maki Ozawa, Ian B. Walters, Toyoko Kikuchi, Patricia Gilleaudeau, Judith L. Bliss, Ullrich S. Schwertschlag, Andrew J. Dorner, James G. Krueger> ;The Journal of Clinical Investigation. 1999 Dec 1
• 338 citations
  THE MAJORITY OF EPIDERMAL T CELLS IN PSORIASIS VULGARIS LESIONS CAN PRODUCE TYPE 1 CYTOKINES, INTERFERON-GAMMA, INTERLEUKIN-2, AND TUMOR NECROSIS FACTOR-ALPHA, DEFININ...
  Lisa M. Austin, Maki Ozawa, Toyoko Kikuchi, Ian B. Walters, James G. Krueger> ;The Journal of Investigative Dermatology. 1999 Nov 1
• 110 citations
  Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris
  Ian B. Walters, Lauren H. Burack, Todd R. Coven, Patricia Gilleaudeau, James G. Krueger> ;Journal of the American Academy of Dermatology. 1999 Jun 1
• 58 citations
  PUVA-induced lymphocyte apoptosis: mechanism of action in psoriasis.
  Todd R. Coven, Ian B. Walters, Irma Cardinale, James G. Krueger> ;Photodermatology, Photoimmunology & Photomedicine. 1999 Feb 1
• Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
  Park, J. W., Finn, R. S., Kim, J. S., Karwal, M., Li, R. K., Ismail, F., Thomas, M., Harris, R., Baudelet, C., Walters, I., Raoul, J. L.> ;Clin Cancer Res. 2011 Apr 1
• Join now to see all